Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Endometrial Neoplasms 3Weight Loss 2Neoplasms 2Cachexia 2Body Weight 2Anorexia 2Recurrence 1Pancreatic Neoplasms 1Menorrhagia 1Lung Neoplasms 1Leiomyoma 1Head and Neck Neoplasms 1Breast Neoplasms 1

Interventions

telapristone acetate 18vilaprisan 12relugolix 11estradiol, norethindrone drug combination 9asoprisnil 9Estradiol 8elagolix 7Uterine Myomectomy 7ulipristal acetate 6Norethindrone Acetate 6Leuprolide 5linzagolix 4Uterine Artery Embolization 3Sugars 3ulipristal 2Progestins 2Mifepristone 2epigallocatechin gallate 1carbetocin 1Vitamin D 1Vitamin B 6 1Therapeutics 1Standard of Care 1Sodium Chloride 1Robotic Surgical Procedures 1Radiofrequency Ablation 1Progesterone 1Microbial Collagenase 1Megestrol Acetate 1Medroxyprogesterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Leiomyoma × Megestrol Acetate × Clear all
NCT06671548 2026-02-02

Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Qilu Pharmaceutical Co., Ltd.

Phase 3 Recruiting
120 enrolled

Leiomyoma, Menorrhagia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡